Drug Trial Radar · NCT04772105
Study of Two Multiple Intravitreal Doses of BAT5906 for Safety and Efficacy in Patients With Diabetic Macular Edema
Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Oct 16, 2020
Primary completion
Nov 6, 2023
Study completion Nov 6, 2023
Sponsor
- Lead sponsor
- Bio-Thera SolutionsIndustry
- Sponsor type
- Industry
- First posted
- Feb 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, open, multiple-dose phase Ib/IIa clinical study evaluating the efficacy and safety of BAT5906 injection in patients with diabetic macular edema. BAT5906's phase I study on w-AMD shows that it is safe from 0.3-4.0 mg, and the higher dose (2.5 mg and 4 mg) may maintain the anti-VEGF effect for a longer time just like the same target drugs (such as brolucizumab and Abecip ) It has also been found in clinical studies that high doses can extend the dosing interval and reduce the dosing frequency. Therefore, in this study, two safe and effective doses were selected, and the optimal clinical effective dose and frequency of BAT5906 in DME were initially explored.
Conditions
- Diabetic Macular Edema
Interventions
2.5mg of BAT5906Drug
Specification: 2.5mg of BAT5906
4.0mg of BAT5906Drug
Specification: 4.0mg of BAT5906
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1.1 Safety evaluation - Vital signs# the patient's body temperature;Time frame: Day-14~Day-1;Day0;Day28;Day56;Day84;Day112;Day140;Day168;Day196;Day224;Day252;Day280;Day308;Day336
- 1.2 Safety evaluation - Vital signs# heart rate/pulseTime frame: Day-14~Day-1;Day0;Day28;Day56;Day84;Day112;Day140;Day168;Day196;Day224;Day252;Day280;Day308;Day336
- 1.3 Safety evaluation - Vital signs# respiratory rateTime frame: Day-14~Day-1;Day0;Day28;Day56;Day84;Day112;Day140;Day168;Day196;Day224;Day252;Day280;Day308;Day336
- 1.4 Safety evaluation - Vital signs# blood pressureTime frame: Day-14~Day-1;Day0;Day28;Day56;Day84;Day112;Day140;Day168;Day196;Day224;Day252;Day280;Day308;Day336
- Number of subjects with clinically significant abnormal physical examination signs identified byprotocol-specified full physical examination (general appearance, skin, lungs, heart, abdomen,extremities, musculoskeletal system)Time frame: Day-14~Day-1;Day84;Day168;Day336
- Number of participants with clinically significant abnormal laboratory findingsTime frame: Day-14~Day-1;Day84;Day168;Day336
- Number of participants with clinically significant abnormal ECG findingsTime frame: Day-14~Day-1;Day84;Day168;Day336
- Anti-drug antibody (ADA);Time frame: Screening (within 24 hours prior to first dose), Day 7 (168h), Day 14 (336h), prior to the 3rd dose (within 24 hours), and prior to the 5th dose through end of study visit (as needed)
- ocular and non-ocular adverse events (AE) and serious adverse events (SAE)Time frame: Adverse events were collected from the time the patient signed the informed consent to the time 28 days after the last dication
- Efficacy evaluationTime frame: at Week 36
- Pharmacokinetic (PK) EvaluationTime frame: Once within 24 hours before administration.6 hours after administration, 24 hours after administration(once every 3 days) up to 672 hours after administration
- Peripheral Blood VEGF Assessment (VEGF)Time frame: Once within 24 hours before administration.24 hours after administration (once every 7 days) up to 672hours after administration
- Immunogenicity AssessmentTime frame: First administration: within 24 hours prior to administration.168 hours and 336 hours after administration,and the second until the last administration: within 24 hours before administration
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Eye Hospital of China Academy of Chinese Medical Sciences
Beijing, China
Peking University First Hospital
Beijing, China
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China
Zhejiang Provincial People's Hospital
Hangzhou, China
Henan Provincial Eye Hospital
Henan, China
Jieyang People's Hospital
Jieyang, China
The First Hospital of Jilin University
Jilin City, China
The Affiliated Eye Hospital of Nanchang University
Nanchang, China
Jiangsu Provincial Hospital of Traditional Chinese Medicine
Nanjing, China
Affiliated Hospital of Nantong University
Nantong, China
Affiliated Hospital of Qingdao University
Qingdao, China
Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong
Shantou, China
West China Hospital of Sichuan University
Sichuan, China
Wenzhou Medical University Affiliated Optometry Hospital
Wenzhou, China
The Second Xiangya Hospital of Central South University
Xiangya, China
Xiangya Hospital Central South University
Xiangya, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijiang, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.